SCHEMBL24367667

SCHEMBL24367667

COc1cc(N)cnc1NC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
MAPKAPK2 P49137 5/20 0.39
ABL1 P00519 2/20 0.39
PIK3CD O00329 1/20 0.39
EGFR P00533 1/20 0.39
KDR P35968 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CG P48736 1/20 0.39
BACE1 P56817 1/20 0.39
PRKDC P78527 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
MAP4K4 O95819 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ATR Q13535 1/20 0.38
CTSL P07711 1/20 0.37
SYK P43405 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
PRMT1 Q99873 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29477633 1.00 ALDH1A1 (0.40) ALDH1A1GAAMAPKAPK2ABL1PIK3CD
SCHEMBL15599368 0.83 AAK1 (0.44) ALDH1A1GAAKDM4EATRCTSL
SCHEMBL30469570 0.83 MAPKAPK2 (0.40) MAPKAPK2MAP4K4ATRSYKPRMT1
SCHEMBL24364156 0.83 MAPKAPK2 (0.40) MAPKAPK2MAP4K4ATRSYKPRMT1
SCHEMBL6517445 0.82 MAPKAPK2 (0.40) MAPKAPK2MAP4K4ATRSYKAAK1
SCHEMBL17604700 0.81 KDM4E (0.44) ALDH1A1GAAMAPKAPK2KDM4EATR
SCHEMBL24364864 0.81 MAP4K4 (0.42) MAPKAPK2ABL1PIK3CDEGFRKDR
SCHEMBL3934366 0.81 CYP1A2 (0.40) ALDH1A1EGFRKDRPIK3CAPIK3CG
SCHEMBL24364867 0.81 MAPKAPK2 (0.41) MAPKAPK2MAP4K4ATRSYKPRMT1
SCHEMBL31430396 0.81 MAPKAPK2 (0.41) MAPKAPK2MAP4K4ATRSYKPRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 ALDH1A1 128/4885GAA 889/4885MAPKAPK2 4853/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 ALDH1A1 128/4885GAA 889/4885MAPKAPK2 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.